Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]:
SEC Accession No. 0001193125-22-262585
Filing Date
2022-10-14
Accepted
2022-10-14 07:05:53
Documents
6
Period of Report
2022-10-14

Document Format Files

Seq Description Document Type Size
1 FORM 6-K d402146d6k.htm 6-K 9073
2 EX-99.1 d402146dex991.htm EX-99.1 236365
3 GRAPHIC g402146g02g02.jpg GRAPHIC 94077
4 GRAPHIC g402146g03g03.jpg GRAPHIC 117495
5 GRAPHIC g402146g04q07.jpg GRAPHIC 8644
6 GRAPHIC g402146sp5.jpg GRAPHIC 1829
  Complete submission text file 0001193125-22-262585.txt   547220
Mailing Address THREE INTERNATIONAL TOWERS LEVEL 24, 300 BARANGAROO AVENUE SYDNEY NSW C3 2000
Business Address THREE INTERNATIONAL TOWERS LEVEL 24, 300 BARANGAROO AVENUE SYDNEY NSW C3 2000 01161298780088
KAZIA THERAPEUTICS LTD (Filer) CIK: 0001075880 (see all company filings)

EIN.: 000000000 | Fiscal Year End: 0630
Type: 6-K | Act: 34 | File No.: 000-29962 | Film No.: 221310257
SIC: 2834 Pharmaceutical Preparations